Literature DB >> 15027857

2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.

Shudong Wang1, Christopher Meades, Gavin Wood, Andrew Osnowski, Sian Anderson, Rhoda Yuill, Mark Thomas, Mokdad Mezna, Wayne Jackson, Carol Midgley, Gary Griffiths, Ian Fleming, Simon Green, Iain McNae, Su-Ying Wu, Campbell McInnes, Daniella Zheleva, Malcolm D Walkinshaw, Peter M Fischer.   

Abstract

Following the identification through virtual screening of 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamines as moderately potent inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analogue program was initiated. The first aims were to optimize potency and to evaluate the cellular mode of action of lead candidate molecules. Here the synthetic chemistry, the structure-guided design approach, and the structure-activity relationships (SARs) that led to the discovery of 2-anilino-4-(thiazol-5-yl)pyrimidine ATP-antagonistic CDK2 inhibitors, many with very low nM K(i)s against CDK2, are reported. Furthermore, X-ray crystal structures of four representative analogues from our chemical series in complex with CDK2 are presented, and these structures are used to rationalize the observed biochemical SARs. Finally results are reported that show, using the most potent CDK2 inhibitor compound from the current series, that the observed antiproliferative and proapoptotic effects are consistent with cellular CDK2 and CDK9 inhibition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027857     DOI: 10.1021/jm0309957

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  26 in total

Review 1.  Ligand discovery and virtual screening using the program LIDAEUS.

Authors:  P Taylor; E Blackburn; Y G Sheng; S Harding; K-Y Hsin; D Kan; S Shave; M D Walkinshaw
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

2.  Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.

Authors:  Petr Dobeš; Jindřich Fanfrlík; Jan Rezáč; Michal Otyepka; Pavel Hobza
Journal:  J Comput Aided Mol Des       Date:  2011-02-01       Impact factor: 3.686

3.  ΔF508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles.

Authors:  Long Ye; Bao Hu; Faris El-Badri; Brandi M Hudson; Puay-Wah Phuan; A S Verkman; Dean J Tantillo; Mark J Kurth
Journal:  Bioorg Med Chem Lett       Date:  2014-10-02       Impact factor: 2.823

4.  In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83.

Authors:  Xiangrui Liu; Frankie Lam; Shenhua Shi; Peter M Fischer; Shudong Wang
Journal:  Invest New Drugs       Date:  2011-02-18       Impact factor: 3.850

Review 5.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

6.  Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication.

Authors:  Akbar Ali; Animesh Ghosh; Robin S Nathans; Natalia Sharova; Siobhan O'Brien; Hong Cao; Mario Stevenson; Tariq M Rana
Journal:  Chembiochem       Date:  2009-08-17       Impact factor: 3.164

7.  Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.

Authors:  Michael B Donald; Kevin X Rodriguez; Hannah Shay; Puay-Wah Phuan; A S Verkman; Mark J Kurth
Journal:  Bioorg Med Chem       Date:  2012-07-06       Impact factor: 3.641

8.  Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death.

Authors:  Xiaoou Xu; Shizuka Eshima; Shinichiro Kato; David E Fisher; Hiroaki Sakurai; Yoshihiro Hayakawa; Satoru Yokoyama
Journal:  Mol Cancer Ther       Date:  2019-11-19       Impact factor: 6.261

Review 9.  Docking screens: right for the right reasons?

Authors:  Peter Kolb; John J Irwin
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

10.  Molecular-docking-guided 3D-QSAR studies of substituted isoquinoline-1,3-(2H,4H)-diones as cyclin-dependent kinase 4 (CDK4) inhibitors.

Authors:  Xiao-Yun Lu; Ya-Dong Chen; Ni-yue Sun; Yong-Jun Jiang; Qi-Dong You
Journal:  J Mol Model       Date:  2009-06-20       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.